VIFOR-PHARMA-GROUP
14.5.2020 17:37:12 CEST | Business Wire | Press release
Regulatory News:
At the 92nd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors.
In view of the current situation and based on Art. 6a of Ordinance 2, issued by the Swiss Federal Council, regarding measures against containment of the coronavirus (COVID-19), shareholders were not permitted to attend the event in person. Shareholders exercised their rights exclusively through the independent proxy and 69% of the share capital was represented.
Shareholder approvals
Shareholders approved the 2019 Vifor Pharma Annual Report, the Vifor Pharma Ltd. 2019 Annual Financial Statements, and the Vifor Pharma Group 2019 Consolidated Financial Statements as well as an extension of the Authorized Capital until 14 May 2022 by approving the respective amendment to the Articles of Association. The maximum possible 2020 remuneration for the Board of Directors and Executive Committee was also approved, as well as the 2019 Remuneration Report in a consultative vote. Shareholders discharged the members of the Board of Directors and the Corporate Executive Committee for the financial year 2019. A dividend of CHF 2.00, as proposed by the Board of Directors, was approved and will be paid to shareholders on 20 May 2020.
Board of Directors re-elections
The Annual General Meeting re-elected all members proposed and elected Gilbert Achermann as new member of the Board of Directors. Shareholders also elected Jacques Theurillat as new Chairman of the Board of Directors, succeeding Etienne Jornod who decided not stand for re-election after 25 years. The Board of Directors sincerely thanks him for many years of distinguished service and recognized his long-standing and successful leadership by appointing him as Honorary Chairman.
The Board of Directors is now composed of the following members: Jacques Theurillat (Chairman), Gilbert Achermann, Prof. Dr. hon. Michel Burnier, Dr. Romeo Cerutti, Dr. Sue Mahony, Kim Stratton and Dr. Gianni Zampieri.
Remuneration Committee confirmed
The following members of the Board of Directors were re-elected to the Remuneration Committee for a term of one year: Prof. Dr. hon. Michel Burnier, Dr. Romeo Cerutti, and Dr. Sue Mahony.
Vifor Pharma Group is a global specialty pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit www.viforpharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005044/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet HaystackID29.1.2026 21:20:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for cybersikkerhed og teknologi gennem en samarbejdsaftale med HaystackID, en amerikansk udbyder af eDiscovery, juridiske data og cyber discovery-tjenester. HaystackID blev stiftet i 2011 og arbejder tæt sammen med advokatfirmaer, virksomheder og offentlige myndigheder om at håndtere komplekse, dataintensive juridiske sager, herunder civile retssager, myndighedsundersøgelser og interne undersøgelser. Firmaet leverer komplet processtøtte ved hjælp af cyber discovery, digital efterforskning, managed review, compliance og information governance, hvilket hjælper klienter med at identificere, analysere og forsvarligt fremlægge kritiske data. Ved hjælp af proprietære ai-drevne platforme og ekspertledede reviewteams betjener HaystackID klienter i hele Nordamerika og Europa, heriblandt Fortune 100-virksomheder. "I takt med at de juridiske og regulatoriske miljøer bliver mere datadrevne og tidskritiske, fortsætter vi med at udvikle vores kompet
Convera Appoints Industry Leader Meaghan Riley as Chief Commercial Officer to Scale Commercial Growth and Expand Revenue Opportunities29.1.2026 17:14:00 CET | Press release
Former Google Cloud and SAP executive will build on Convera’s success and leadership in the commercial payments sector Convera, a global leader in commercial payments, today announces the appointment of Meaghan Riley to Chief Commercial Officer, as the company continues its growth trajectory, expands to new markets, and drives scalable revenue opportunities across geographies and sectors. Prior to Convera, Meaghan was Chief Operating Officer for Google Cloud North America, where she led a major go-to-market transformation and launched high-growth segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129799440/en/ Meaghan Riley, Chief Commercial Officer, Convera “Meaghan’s impressive career journey and proven track record brings exceptional experience and unique assets that will strengthen our leadership team at this pivotal moment in Convera’s journey,” said Patrick Gauthier, CEO, Convera. “Meaghan’s leadership will be
New Year, New Solutions: AMRA Medical Continues Commitment to Innovation & Data-Driven Excellence29.1.2026 16:23:00 CET | Press release
AMRA Medical, the global leader in MRI-based fat distribution and muscle composition analytics, is excited to share our brand repositioning supported by the launch of a refreshed website and the introduction of a new tagline, “Insights Within.” This strategic update reflects AMRA’s commitment to placing clients and collaborators at the center of our vision: to be the most trusted, insights-driven imaging partner in the pursuit of preventing and curing disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129457626/en/ The new website provides a more structured and transparent presentation of AMRA’s biomarkers and research services, enabling our partners to have a clear understanding of our offerings, as well as the scientific value and applications of these solutions. For the first time, we’re introducing Imaging Biomarkers and Insights Biomarkers: clearly-defined, intentional offerings that are designed with your trial
NTT DATA Signs Strategic Collaboration Agreement with AWS to Accelerate Enterprise Cloud and Agentic AI Adoption29.1.2026 14:00:00 CET | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced a multi-year Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to help enterprises modernize legacy systems, adopt agentic AI responsibly and scale innovation across industries. Combining NTT DATA’s expertise in cloud transformation, cloud-native modernization and Agentic AI with the scale and innovation velocity of AWS services, the collaboration will deliver tailored enterprise solutions that modernize mission-critical workloads, build secure cloud foundations and drive measurable business outcomes across regulated and high-growth industries. Under the agreement, NTT DATA and AWS will accelerate enterprise transformation in four priority areas: AI-driven large-scale cloud transformation: Accelerating the migration and modernization of on-premises workloads on AWS, leveraging generative and agentic AI, automation and data platforms to unlock new business models and drive int
U.S. Department of Energy and Kyoto Fusioneering Launch Strategic Partnership to Build Critical Fusion Infrastructure and Accelerate Deployment of Commercial Fusion Power29.1.2026 14:00:00 CET | Press release
Today, the U.S. Department of Energy (DOE) and Kyoto Fusioneering (KF) established a landmark partnership to deliver critical fusion infrastructure and perform collaborative R&D to drive down technology and commercialization risk. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127164854/en/ Anchored by a new public-private partnership between KF and Oak Ridge National Laboratory (ORNL) that leverages each institution’s expertise in fusion technology to develop world-leading fusion test facilities and technology, this agreement establishes a new paradigm in U.S.-Japan allied cooperation and public-private partnership towards accelerating the deployment of commercial fusion power. Under the new partnership, KF and ORNL will commence joint research and development activities focused on fusion breeding blanket systems, a critical technology for producing the tritium fuel needed to sustain fusion power generation. This include
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom